Posted inMarket
Vaxcyte Stock Rises Following Leadership Updates and VAX-31 Timeline
Vaxcyte shares climbed following the appointment of new executives and the announcement of an upcoming timeline for VAX-31 clinical data.
Posted inMarket
Vaxcyte Strengthens Leadership Team and Accelerates Clinical Trial Timeline
Vaxcyte appoints two new executive leaders and narrows the anticipated trial timeline for its key pneumococcal conjugate vaccine candidate.
